Literature DB >> 18218640

Susceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutations.

Yonghao Xu1, Lamei Chen, Chunyang Li.   

Abstract

OBJECTIVES: To investigate fluconazole susceptibility of Candida albicans from non-AIDS patients and to analyse the relationship between mutations in the ERG11 gene of these isolates and fluconazole resistance.
METHODS: Four hundred and twenty-six clinical isolates of Candida species were collected. Fluconazole susceptibility was tested in vitro using microdilution and disc diffusion assays. The ERG11 genes of 23 isolates of C. albicans (8 susceptible and 15 resistant) and 6 type strains (4 susceptible and 2 resistant) were amplified in three overlapping regions of the gene and sequenced.
RESULTS: Of the 426 isolates collected, 68.6% were C. albicans; however, only 5.1% were resistant to fluconazole. Eighteen silent mutations and 19 missense mutations were detected. There were six missense mutations only in resistant isolates or resistant type strains: (i) G487T (A114S) and T916C (Y257H) appeared simultaneously in 14 fluconazole-resistant isolates without any other mutation; these may be associated with resistance; (ii) T541C (Y132H) and T1559C (I471T) are known to contribute to fluconazole resistance; and (iii) C1567A (Q474K) or a novel mutation T1493A (F449Y) was identified but correlations with resistance have not been studied.
CONCLUSIONS: In this survey, C. albicans is the major cause of candidiasis in non-AIDS patients, and some isolates that are resistant to fluconazole have G487T and T916C mutations in ERG11 that are associated with fluconazole resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18218640     DOI: 10.1093/jac/dkn015

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Authors:  Andrew G S Warrilow; Claire M Martel; Josie E Parker; Nadja Melo; David C Lamb; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

2.  Evaluation of the V404I and V509M amino acid substitutions of ERG11 gene in Candida albicans isolates by pyrosequencing.

Authors:  T-H Kim; M-K Lee
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

3.  A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.

Authors:  Claire M Martel; Josie E Parker; Oliver Bader; Michael Weig; Uwe Gross; Andrew G S Warrilow; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 4.  Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans.

Authors:  Andrew T Nishimoto; Cheshta Sharma; P David Rogers
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

5.  Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.

Authors:  Claire M Martel; Josie E Parker; Oliver Bader; Michael Weig; Uwe Gross; Andrew G S Warrilow; Nicola Rolley; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

6.  A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.

Authors:  Isabelle Accoceberry; Amandine Rougeron; Nicolas Biteau; Pauline Chevrel; Valérie Fitton-Ouhabi; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.

Authors:  Stephanie A Flowers; Brendan Colón; Sarah G Whaley; Mary A Schuler; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

8.  Update on Antifungal Drug Resistance.

Authors:  David S Perlin; Erika Shor; Yanan Zhao
Journal:  Curr Clin Microbiol Rep       Date:  2015-06-01

9.  Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.

Authors:  S M Heimann; O A Cornely; H Wisplinghoff; M Kochanek; D Stippel; S A Padosch; G Langebartels; H Reuter; M Reiner; A Vierzig; H Seifert; M J G T Vehreschild; J Glossmann; B Franke; J J Vehreschild
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-12       Impact factor: 3.267

10.  Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing.

Authors:  Huiping Wang; Fanrong Kong; Tania C Sorrell; Bin Wang; Paul McNicholas; Namfon Pantarat; David Ellis; Meng Xiao; Fred Widmer; Sharon Ca Chen
Journal:  BMC Microbiol       Date:  2009-08-14       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.